Navigation Links
Second-most common breast cancer subtype may benefit from personalized treatment approach
Date:2/25/2014

PITTSBURGH, Feb. 26, 2014 The second-most common type of breast cancer is a very different disease than the most common and appears to be a good candidate for a personalized approach to treatment, according to a multidisciplinary team led by University of Pittsburgh Cancer Institute (UPCI) scientists.

Invasive lobular carcinoma, which is characterized by a unique growth pattern in breast tissue that fails to form a lump, has distinct genetic markers that indicate there may be benefits from drug therapies beyond those typically prescribed for the more common invasive ductal carcinoma. The results will be published in the March 1 issue of the journal Cancer Research.

Patients with invasive lobular carcinoma are typically treated through surgical removal of the cancer, followed by chemotherapy or hormone therapy or both, usually with the estrogen-mimicking drug tamoxifen or estrogen-lowering aromatase inhibitors, the same as patients with invasive ductal carcinoma.

"However, recent analyses have shown that a subset of patients with lobular carcinoma receive less benefit from adjuvant tamoxifen than patients with ductal carcinoma," said senior author Steffi Oesterreich, Ph.D., professor at UPCI, a partner with UPMC CancerCenter, and director of education at the Women's Cancer Research Center. "Our study, the largest of its kind, indicates an issue with the estrogen receptors inside lobular carcinoma cells and points to a potential target for drug therapy in future clinical trials, which we are developing."

The UPCI study, funded by the Breast Cancer Research Foundation and the U.S. Department of Defense, included collaborations across multiple disciplines, ranging from biostatistics and biomedical informatics to pathology and human genetics, in order to produce results with the potential for rapid translation into clinical therapies.

"In addition to its potential clinical implications, the study highlights the need for more and better models mimicking invasive lobular cancer that can be used for laboratory studies," said lead author Matthew Sikora, Ph.D., a postdoctoral associate at UPCI.

"Because lobular carcinomas account for only 10 to 15 percent of breast cancers, while ductal carcinomas make up nearly 80 percent, lobular carcinomas are a less attractive option for laboratory study," said Dr. Sikora. "However, 30,000 women in the U.S. are diagnosed with lobular carcinoma every year, so there is a great need for further study of this disease."


'/>"/>

Contact: Allison Hydzik
hydzikam@upmc.edu
412-647-9975
University of Pittsburgh Schools of the Health Sciences
Source:Eurekalert  

Related biology news :

1. Finding common ground fosters understanding of climate change
2. Common crop pesticides kill honeybee larvae in the hive
3. Arctic cyclones more common than previously thought
4. How common is aggression in UK dogs?
5. Walking the walk: What sharks, honeybees and humans have in common
6. Study of rodent family tree puts brakes on commonly held understanding of evolution
7. Human error most common cause of birth asphyxia
8. Gene linked to common intellectual disability
9. Model virus structure shows why theres no cure for common cold
10. Common bias known as the endowment effect not present in hunter-gatherer societies
11. OU research team finds a common bioindicator resistant to insecticides
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Second-most common breast cancer subtype may benefit from personalized treatment approach
(Date:11/19/2016)... 18, 2016 Securus Technologies, a leading provider ... safety, investigation, corrections and monitoring, announced today that it ... to have an independent technology judge determine who has ... high tech/sophisticated telephone calling platform, and the best customer ... do most of what we do – which clearly ...
(Date:11/17/2016)... it has just released a new white paper authored by Zettar that covers the ... transfer storage solutions. Photo - http://photos.prnewswire.com/prnh/20161116/440463 ... ... ... Setting up a high performance computing or HPC system can be a complicated endeavor ...
(Date:11/15/2016)... , Nov. 15, 2016  Synthetic Biologics, Inc. ... therapeutics focused on the gut microbiome, today announced ... 25,000,000 shares of its common stock and warrants ... at a price to the public of $1.00 ... Synthetic Biologics from the offering, excluding the proceeds, ...
Breaking Biology News(10 mins):
(Date:12/6/2016)... MELBOURNE, Australia , Dec. 6, 2016  The ... Health Informatics Society of Australia (HISA) today announced ... technology startup exchange program between Australia ... city in the world. HISA and ... are initiating a program to create a global health ...
(Date:12/5/2016)... 2016 Axovant Sciences Ltd. (NYSE: ... the treatment of dementia, today announced that data on ... Alzheimer,s disease will be presented at the 2016 Clinical ... 9, 2016 in San Diego . ... simple and complex measures of activities of daily living ...
(Date:12/5/2016)... ... December 05, 2016 , ... The Real Dirt ... premier cannabis technology and application experts, Chip Baker. Chip Baker formerly co-founded Royal ... the past 30 years, Chip Baker other industry veterans have made the evolution ...
(Date:12/5/2016)... , Dec. 5, 2016  Renova™ Therapeutics, ... congestive heart failure and other chronic diseases, announced ... the company as Chief Financial Officer (CFO), effective ... with 20 years of experience in financial management ... biotech and software companies. Most recently, Ms. Bovenizer ...
Breaking Biology Technology: